Research advances in predictive markers for HBeAg seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogues
10.3969/j.issn.1001-5256.2020.06.036
- VernacularTitle:核苷（酸）类似物治疗慢性乙型肝炎发生HBeAg血清学转换的预测标志物
- Author:
Yingying JIANG
1
;
Sujun ZHENG
Author Information
1. Department of Severe Liver Disease
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
hepatitis B e antigens;
nucleosides;
nucleotides
- From:
Journal of Clinical Hepatology
2020;36(6):1358-1361
- CountryChina
- Language:Chinese
-
Abstract:
Nucleos(t)ide analogues (NAs) are effective inhibitors for HBV replication and have become the preferred antiviral regimen for most patients with chronic hepatitis B (CHB). HBeAg seroconversion is an important index used to evaluate the durability and efficacy of antiviral therapy in HBeAg-positive CHB patients. The search for biomarkers that can predict HBeAg clearance or seroconversion after NAs treatment plays an important role in the selection of antiviral drugs, the adjustment of treatment regimens, and the achievement of individualized treatment. This article reviews the value of related markers, including HBV DNA, HBV RNA, anti-HBc, and HBcrAg, in predicting HBeAg clearance or seroconversion in CHB patients treated with NAs.
